Medicine and Dentistry
Analysis
100%
Health Care Cost
100%
Avelumab
100%
Merkel Cell Carcinoma
100%
Therapeutic Procedure
85%
Patient
57%
Quality Adjusted Life Year
57%
Cost-Effectiveness Analysis
42%
Supportive Care
42%
Disease
28%
Survival
14%
Prognosis
14%
Death
14%
Health Status
14%
Progression Free Survival
14%
Chemotherapy Regimens
14%
Programmed Death 1 Ligand 1
14%
Human Monoclonal Antibody
14%
Nursing and Health Professions
Cost Utility Analysis
100%
Merkel Cell Carcinoma
100%
Avelumab
100%
Quality Adjusted Life Year
57%
Chemotherapy
42%
Incremental Cost-Effectiveness Ratio
42%
Diseases
28%
Analysis
14%
Death
14%
Prognosis
14%
Literature Review
14%
Health Status
14%
Survival
14%
Progression Free Survival
14%
Programmed Death 1 Ligand 1
14%
Human Monoclonal Antibody
14%
Pharmacology, Toxicology and Pharmaceutical Science
Avelumab
100%
Merkel Cell Carcinoma
100%
Chemotherapy
42%
Diseases
28%
Death
14%
Survival
14%
Prognosis
14%
Human Monoclonal Antibody
14%
Health Status
14%
Progression Free Survival
14%
Programmed Death 1 Ligand 1
14%